articleTop 1% cited
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology · 2013 · Vol. 31(27) · pp. 3327–3334
Lecia V. Sequist✉James Chih‐Hsin YangNobuyuki YamamotoKenneth J. O’ByrneVera HirshTony MokSarayut Lucien GeaterС. В. ОрловChun‐Ming TsaiMichael BoyerWu‐Chou SuJaafar BennounaTerufumi KatoВ. А. Горбунова(Angiologica (Italy))Ki Hyeong LeeRiyaz Shah(Maidstone and Tunbridge Wells NHS Trust)Dan Massey(Boehringer Ingelheim (Egypt))Victoria Zazulina(Boehringer Ingelheim (Egypt))Mehdi Shahidi(Boehringer Ingelheim (Egypt))Martin Schüler
Abstract
Afatinib is associated with prolongation of PFS when compared with standard doublet chemotherapy in patients with advanced lung adenocarcinoma and EGFR mutations.
Lung Cancer Treatments and MutationsPeptidase Inhibition and AnalysisCancer therapeutics and mechanismsAfatinibMedicinePemetrexedInternal medicineEpidermal growth factor receptorOncologyAdenocarcinomaLung cancerChemotherapyPhases of clinical research
MeSH terms
PemetrexedAdenocarcinoma of LungAfatinibAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCisplatinFemaleGlutamatesGuanineHumansLung NeoplasmsMale
Citations
3,181
FWCI
217.04
field-weighted impact
References
35
Percentile
100%
vs. same field & year
Citations per year
Cited by
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Cancers · 2020 · 498 citations
The prevalence of <i>EGFR</i> mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Oncotarget · 2016 · 768 citations
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
The Lancet Oncology · 2015 · 1,573 citations
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2016 · 2,632 citations
Tumor angiogenesis: causes, consequences, challenges and opportunities
Cellular and Molecular Life Sciences · 2019 · 1,863 citations
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2018 · 2,268 citations
Cell death-based treatment of lung adenocarcinoma
Cell Death and Disease · 2018 · 781 citations
References
Interpreting the significance of changes in health-related quality-of-life scores.
Journal of Clinical Oncology · 1998 · 2,890 citations
Epidermal growth factor receptor mutations in lung cancer
Nature reviews. Cancer · 2007 · 3,115 citations
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Science Translational Medicine · 2011 · 3,534 citations
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
PLoS Medicine · 2005 · 3,519 citations
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
Oncogene · 2009 · 979 citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Oncogene · 2008 · 1,434 citations
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Journal of Clinical Oncology · 2008 · 3,206 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.